leisure time -WSS

leisure time

author：fashion 2025-09-03 03:24:47 - browse：322

At some point this summer, the drugmaker Novo Nordisk will release results from a closely watched study that, if successful, could further uncork demand for new obesity medications, streamline insurance coverage for the therapies, and demonstrate long-lasting health benefits.

The Select trial, as the study is called, is the first large, randomized trial to test whether long-term treatment with a weight loss drug can meaningfully improve patients’ cardiovascular health. Novo is testing Wegovy, a weekly injection also sold under the brand name Ozempic for type 2 diabetes, against placebo in the five-year study.

The implications are massive, and not just for Novo. Wegovy is part of a class of medicines that target a hormone called GLP-1, which curbs patients’ appetites. Those drugs have demonstrated an ability to help people lose dramatic amounts of weight in clinical trials, but payers, including Medicare, have been slow to reimburse for them without definitive data on their long-term health benefits.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Was Amgen transparent enough on FDA's concern on cancer drug?

entertainment

WSS

VC firm General Catalyst wants to buy a health system

Liquid biopsy for lung cancer is launched by Delfi

Bristol 'take

Was Amgen transparent enough on FDA's concern on cancer drug?

What to expect at HLTH 2023, the health care industry conference

Sana to lay off nearly a third of staff, de

focus

leisure time

leisure time

Cancer drug shortages should be causing more outrage

FDA rejects Alnylam's heart disease treatment over insufficient data

Hollywood unions extend contract negotiations for actors

FDA panel signals lack of confidence in Amgen cancer drug data

Peter Hotez and the public health issue of online harassment

Wild otter attack leads to woman being airlifted to hospital, 2 others treated for injuries

In Memoriam: Notable people who died in 2023

Liquid biopsy for lung cancer is launched by Delfi

United colonoscopy coverage change 'may cost lives,' doctors say

A Q&A with the global head of Boehringer Ingelheim's innovation unit

explore

White House drug shortage group privately met with industry

Liquid biopsy for lung cancer is launched by Delfi

'Ancient DNA,' 23andMe reveal African American ancestries

White House drug shortage group privately met with industry

Stroke deaths set to near 10 million globally by 2050

Influencer to be charged after chaos erupts in New York City's Union Square

Wikipedia

hotspot

entertainment

hotspot